R. Hanna, M.D., et al. Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial. Presented at the American Society of Hematology (ASH) Annual Meeting and Exposition. December 7-10, 2024.